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Abstract
Purpose
The purpose of this study is to compare optic disc dose (ODD) between 125I and 103Pd Collaborative Ocular
Melanoma Study (COMS) plaques in ocular brachytherapy.
Methods
A previously validated in-house brachytherapy dose calculation program was used for ODD calculations.
ODD was calculated as a function of tumor margin-to-optic disc distance (DT) up to 5 mm for various tumor
basal dimensions (BDs), for a prescription depth of 5 mm, and for standard and notched COMS plaques
loaded with 125I (model: IAI-125A) and 103Pd (model: IAPd-103A) seeds. ODD calculations were repeated for
prescription depths from 2 mm to 10 mm in 1 mm intervals. A prescribed dose of 85 Gy (irradiation time:
120 hours) was normalized to each prescription depth. Dose conversion factors (DCFs) for each prescription
depth were calculated by taking a ratio of [total reference air kerma (TRAK) per seed]prescription depth to
[TRAK per seed]5 mm. ODD reduction by notched COMS plaques was calculated for each prescription depth
by subtracting ODD for notched COMS plaques from ODD for standard COMS plaques.
Results
Trends of ODD as a function of DT for various BDs are similar between the two seed types in both standard
and notched COMS plaques. However, due to the energy difference, there exists a transition distance (dt) for
each BD in each plaque at which ODD for 125I COMS plaques equals that for 103Pd COMS plaques. For small
BDs, at DT <dt, ODD for 
103Pd COMS plaques is higher than that for 125I COMS plaques while at DT >dt, the
opposite is observed. For the largest 1-3 BD(s), contrarily, dt occurs within the tumor, and thus, ODD for 
125I
COMS plaques is always higher. Trends of ODD reduction by notched COMS plaques as a function of DT for
various BDs are the same for the two seed types except that maximum ODD reduction by 103Pd COMS
notched plaques is larger. DCF increases with increasing prescription depth for both seed types.
Conclusions
There exist ODD differences between 125I and 103Pd COMS plaques and the differences depend on DT, BD,
plaque size, and prescription depth.
Categories: Medical Physics, Ophthalmology, Radiation Oncology
Keywords: optic disc dose, 125i, 103pd, coms plaques, ocular brachytherapy
Introduction
In the mid-1980s, the Collaborative Ocular Melanoma Study (COMS) established standardized methods of
125I plaque brachytherapy for medium-sized (apical height from 2.5 mm to 10.0 mm and maximal tumor
basal dimension (BD) of ≤16 mm) choroidal melanomas and conducted a prospective randomized clinical
trial comparing 125I plaque brachytherapy with enucleation [1-3]. The COMS trial showed no significant
survival benefit for enucleation [4,5]. Since then, plaque brachytherapy has become the most widely used
eye- and vision-preserving treatment for uveal melanomas [6,7], and among multiple plaque designs, COMS
plaques loaded with 125I seeds are the most common [2].
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brachytherapy in North America [3]. Physical characteristics such as low average photon energies (28 keV for
125I and 21 keV for 103Pd) and relatively short half-lives (60 days for 125I and 17 days for 103Pd) have made
both radionuclides suitable for plaque brachytherapy [2,3,8]. In 2009, Finger et al. reported improved local
control and visual acuity outcomes with 103Pd plaques compared to using 125I plaques [9]. Their study
included patients (92%) who were eligible for the COMS trial but refused to participate in the trial as well as
those (8%) who were ineligible for the trial due to tumor size (3% of small-sized tumors and 5% of large-
sized tumors). Several dosimetry studies have supported these clinical outcomes: with 103Pd plaques, the
dose is increased within the tumor but decreased in most normal ocular structures when the equivalent dose
is prescribed to the tumor apex [8-11]. This is due to the lower photon energy of 103Pd seeds resulting in a
more rapid dose fall-off with distance compared with 125I seeds [9].
In our first simulation study, optic disc dose (ODD) as a function of distance from the tumor for standard
COMS plaques loaded with 125I seeds was comprehensively investigated [12]. The investigation was made for
three commercially available seed models (IsoAid Advantage IAI-125A, Best Industries 2301, and Bebig
I25.S16) and for various prescription depths from 1 mm to 10 mm in 1 mm intervals. In the second
simulation study, ODD reduction by notched COMS plaques with one and two seeds removed as a function of
distance from the tumor was comprehensively investigated in comparison with ODD for standard COMS
plaques [13]. The second study was performed for only one 125I seed model (IAI-125A) and for various
prescription depths from 1 mm to 10 mm in 1 mm intervals. In both studies, based on our institutional
practice, a prescribed dose of 85 Gy for an irradiation time of 168 hours (seven-day implant) was normalized
to each prescription depth [12,13].
In this study, ODD as a function of distance from the tumor was compared between COMS plaques loaded
with 125I seeds (model: IAI-125A, IsoAid LLC, Port Richey, FL) and COMS plaques loaded with 103Pd seeds
(model: IAPd-103A, IsoAid LLC). Both standard COMS plaques and notched COMS plaques with one seed
removed and with two seeds removed were included in this study. Following the recent American
Brachytherapy Society (ABS) guidelines and clinical practice of institutions using 103Pd plaques [3,14], 85 Gy
for an irradiation time of 120 hours (five-day implant) was prescribed to the tumor apex for both 125I and
103Pd COMS plaques. For this simulation study, an in-house brachytherapy dose calculation program,
developed using MATLAB® software (vR2016a, MathWorks, Natick, MA) and previously validated against
several commercial treatment planning systems [12], was used. Most clinics using COMS plaques follow the
American Association of Physicists in Medicine Task Group (AAPM TG)-43 calculation without
heterogeneity corrections. In this study, therefore, dose calculations were performed following the current
clinical practice. Reporting ODD calculated using a more accurate dosimetry tool such as a Monte Carlo
simulation is out of scope in this study.
Materials And Methods
ODD for 125I and 103Pd standard COMS plaques: prescription depth of 5
mm
Using our validated brachytherapy dose calculation program [12], ODD for standard COMS plaques loaded
with 125I seeds (model: IAI-125A) was calculated as a function of tumor margin (i.e., tumor edge)-to-optic
disc distance (DT) up to 5 mm for various BDs. According to COMS protocols [1], BD of the tumor is defined
as the basal dimension at the center in the direction from the optic disc (Figure 1(a)). The largest dimension
of the tumor determines plaque size and is not always the same as BD. Based on the definition of medium-
sized (maximal BD of ≤16 mm) tumors and a 2-3 mm margin around the tumor [2], calculations were
performed for seven different-sized plaques from 10 mm to 22 mm in diameter in 2 mm increments. For
each plaque, BDs up to (plaque diameter - 4) mm in 2 mm increments were included for calculations but
small BDs <(plaque diameter - 4)/2 mm (even numbers) for 12 mm, 16 mm and 20 mm plaques or small BDs
<(plaque diameter - 4)/2 - 1 mm (even numbers) for 10 mm, 14 mm, 18 mm, and 22 mm plaques were
excluded. A prescribed dose of 85 Gy for an irradiation time of 120 hours was normalized to a central-axis
depth of 5 mm. BD of the tumor and DT in a fundus diagram and apical height of the tumor in a cross-
section of the eye are illustrated in Figure 1.
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FIGURE 1: (a) A fundus diagram showing BD of the tumor and DT and
(b) a cross-section of the eye showing the apical height of the tumor
BD: basal dimension, DT: tumor margin-to-optic disc distance.
In the same fashion, ODD for standard COMS plaques loaded with 103Pd seeds (model: IAPd-103A) was
calculated as a function of DT up to 5 mm for various BDs. Calculations were performed for seven plaques
from 10 mm to 22 mm. The same dose (85 Gy) for the same irradiation time (120 hours) was prescribed to a
central-axis depth of 5 mm.
ODD for 125I and 103Pd notched COMS plaques: prescription depth of 5
mm
Notched plaques are used to accommodate the optic disc when the tumor is adjacent to it (Figure 2).
Notched COMS plaques were designed to remove one seed but two seeds can be removed. In this study,
therefore, two cases (notched COMS plaques with one seed removed and with two seeds removed) were
considered. For one seed removal, six different-sized notched plaques from 12 mm to 22 mm in diameter in
2 mm increments were included. A 10 mm plaque was excluded because a notched plaque design is not
available for this plaque. Removed seed position numbers in Figure 1 of the AAPM TG-129 report were 3, 4,
4, 5, 5, and 5 for 12 mm, 14 mm, 16 mm, 18 mm, 20 mm, and 22 mm plaques, respectively [2]. For two seeds
removal, five different-sized notched plaques from 14 mm to 22 mm were included. A 12 mm plaque was
excluded because its seed configuration does not allow for two seeds removal. Removed seed position
numbers were (4, 9), (4, 10), (5, 12), (5, 13), and (5, 12) for 14 mm, 16 mm, 18 mm, 20 mm, and 22 mm
plaques, respectively [2].
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FIGURE 2: A photo of standard (top row) and notched (bottom row)
COMS plaques with diameters from 12 mm to 20 mm in 2 mm
increments
COMS: Collaborative Ocular Melanoma Study.
ODD for notched COMS plaques loaded with 125I seeds (model: IAI-125A) was calculated as a function of DT
up to 5 mm for various BDs. Calculations were performed for one seed removal (plaques from 12 mm to 22
mm) and two seeds removal (plaques from 14 mm to 22 mm). A BD range for each notched COMS plaque
was the same as for the corresponding standard COMS plaque. After seed(s) were removed from standard
COMS plaques, 85 Gy for an irradiation time of 120 hours was normalized to a central-axis depth of 5 mm.
In the same fashion, ODD for notched COMS plaques loaded with 103Pd seeds (model: IAPd-103A) was
calculated as a function of DT up to 5 mm for various BDs. Calculations were performed for one seed removal
(plaques from 12 mm to 22 mm) and two seeds removal (plaques from 14 mm to 22 mm). The same dose (85
Gy) for the same irradiation time (120 hours) was prescribed to a central-axis depth of 5 mm after seed(s)
were removed.
Dose conversion factors for different prescription depths
Dose conversion factors (DCFs) for different prescription depths were generated for 125I standard COMS
plaques and 103Pd standard COMS plaques. ODD calculations for 125I standard COMS plaques were repeated
for various central-axis depths from 2 mm to 10 mm in 1 mm intervals based on the definition of medium-
sized tumors (apical height from 2.5 mm to 10.0 mm). For each prescription depth, calculations were
performed for seven different-sized plaques from 10 mm to 22 mm in diameter. A prescribed dose of 85 Gy
for an irradiation time of 120 hours was normalized to each depth. For each depth and each plaque, total
reference air kerma (TRAK = air kerma strength Sk × irradiation time, unit: μGym2) per seed was calculated.
Then, DCF for each depth and each plaque was obtained by calculating a ratio of [TRAK per seed]prescription
depth/[TRAK per seed]5 mm where a prescription depth ranges from 2 mm to 10 mm in 1 mm intervals.
Likewise, DCFs for 103Pd standard COMS plaques were obtained. DCFs will allow for estimating ODD at any
prescription depth by multiplying ODD at 5 mm by DCF at a depth of interest.
In addition, DCFs for different prescription depths were generated for 125I notched COMS plaques and 103Pd
notched COMS plaques. ODD calculations for 125I notched COMS plaques were repeated for various
prescription depths from 2 mm to 10 mm in 1 mm intervals. For each prescription depth, calculations were
performed for one seed removal (plaques from 12 mm to 22 mm) and two seeds removal (plaques from 14
mm to 22 mm). The same dose (85 Gy) for the same irradiation time (120 hours) was prescribed to each depth
after seed(s) were removed. TRAK per seed for each depth and each plaque was calculated and then DCF for
each depth and each plaque was obtained in the same way as for 125I standard COMS plaques. Likewise,
DCFs for 103Pd notched COMS plaques were obtained.
ODD reduction by 125I and 103Pd notched COMS plaques
From ODDs for 125I standard COMS plaques and 125I notched COMS plaques, ODD reduction by 125I notched
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COMS plaques was calculated as a function of DT for various BDs. Absolute ODD reduction, 
, was computed using equation (1). Calculations were performed for prescription
depths from 2 mm to 10 mm in 1 mm intervals and for one seed removal (plaques from 12 mm to 22 mm)
and two seeds removal (plaques from 14 mm to 22 mm).
  (1)
ODD reduction by 103Pd notched COMS plaques was also calculated as a function of DT for various BDs. 
 was computed for prescription depths from 2 mm to 10 mm and for one seed removal
(plaques from 12 mm to 22 mm) and two seeds removal (plaques from 14 mm to 22 mm) using equation (1).
Results
ODD comparison between 125I and 103Pd standard COMS plaques:
prescription depth of 5 mm
Figure 3(a)-3(g) shows plots of ODD for 125I versus 103Pd standard COMS plaques as a function of DT for
various BDs when 85 Gy was prescribed to a central-axis depth of 5 mm. Trends of ODD for 125I standard
COMS plaques are similar to those for 103Pd standard COMS plaques. ODD for both seed types usually
decreases as DT and BD increase. On the other hand, there are differences in ODD between 125I and 103Pd
standard COMS plaques. Compared with that for 125I plaques, ODD for 103Pd plaques is higher, becomes the
same, and then is lower as DT increases. Therefore, for each BD (excluding the largest 1-2 BDs) in each
plaque, there exists a transition distance (dt) at which ODD for 
103Pd standard plaques is equivalent to ODD
for 125I standard plaques. For each plaque, dt becomes closer to the optic disc by about 1 mm with increasing
BD by 2 mm. For the largest 1-2 BDs in plaques ≥18 mm, however, dt occurs within the tumor, and as a
result, ODD for 125I standard plaques is always higher than ODD for 103Pd standard plaques.
ODD (Gy)reduction Abs
ODD (Gy) = ODDstandard − ODDnotchedreduction Abs
ODD (Gy)reduction Abs
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FIGURE 3: (a)-(g) An ODD comparison between 125I and 103Pd standard
COMS plaques as a function of DT for various BDs.
A prescribed dose of 85 Gy was normalized to a central-axis depth of 5 mm. ODD: optic disc dose, COMS:
Collaborative Ocular Melanoma Study, DT: tumor margin-to-optic disc distance, BD: basal dimension.
ODD comparison between 125I and 103Pd notched COMS plaques:
prescription depth of 5 mm
Figure 4(a)-4(f) shows plots of ODD for 125I versus 103Pd notched COMS plaques with one seed removed as a
function of DT for various BDs when 85 Gy was prescribed to a central-axis depth of 5 mm. As for standard
COMS plaques, trends of ODD for 125I notched COMS plaques are similar to those for 103Pd notched COMS
plaques: ODD for both seed types usually decreases as DT and BD increase. Also, trends of an ODD
comparison between the two seed types for notched plaques are similar to those for standard plaques: dt, at
which ODD for 103Pd notched plaques equals ODD for 125I notched plaques, exists for each BD (excluding
the largest 1-3 BDs) in each plaque and ODD for 103Pd notched plaques is higher than that for 125I notched
plaques at DT <dt but the opposite is observed at DT >d t. For the largest 1-3 BDs, ODD for 
125I notched
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plaques is always higher.
FIGURE 4: (a)-(f) An ODD comparison between 125I and 103Pd notched
COMS plaques with one seed removed as a function of DT for various
BDs.
A prescribed dose of 85 Gy was normalized to a central-axis depth of 5 mm after one seed was removed from
standard COMS plaques. ODD: optic disc dose, COMS: Collaborative Ocular Melanoma Study, DT: tumor
margin-to-optic disc distance, BD: basal dimension.
ODD for 125I versus 103Pd notched COMS plaques with two seeds removed as a function of DT for various
BDs are plotted in Figure 5(a)-5(e). Trends of an ODD comparison between 125I and 103Pd notched plaques
with two seeds removed are similar to those with one seed removed but ODD for two seeds removal is lower.
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FIGURE 5: (a)-(e) An ODD comparison between 125I and 103Pd notched
COMS plaques with two seeds removed as a function of DT for various
BDs.
A prescribed dose of 85 Gy was normalized to a central-axis depth of 5 mm after two seeds were removed
from standard COMS plaques. ODD: optic disc dose, COMS: Collaborative Ocular Melanoma Study, DT:
tumor margin-to-optic disc distance, BD: basal dimension.
ODD reduction comparison between 125I and 103Pd notched COMS
plaques: prescription depth of 5 mm
Figure 6(a)-6(f) shows plots of ODD reduction by 125I versus 103Pd notched COMS plaques with one seed
removed as a function of DT for various BDs when 85 Gy was prescribed to a central-axis depth of 5 mm.
These plots were obtained by subtracting plots in Figure 4(a)-4(f) from plots in Figure 3(b)-3(g). Trends for
125I notched plaques are the same as those for 103Pd notched plaques except that ODD reduction is larger
with 103Pd notched plaques. ODD reduction increases with increasing DT, reaches the maximum value (
), and then decreases with increasing DT. Contrarily, for the largest 1-2 BDs, ODD
reduction decreases continuously with increasing DT and thus,  occurs at 0 mm.
Excluding the largest 1-2 BDs, differences of  between 103Pd and 125I notched
plaques are 5.1 Gy, 3.8 Gy, 4.3 Gy, 3.4 Gy, 3.5 Gy, and 4.5 Gy for 12 mm, 14 mm, 16 mm, 18 mm, 20 mm, and
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FIGURE 6: (a)-(f) An ODD reduction comparison between 125I and 103Pd
notched COMS plaques with one seed removed as a function of DT for
various BDs.
A prescribed dose of 85 Gy was normalized to a central-axis depth of 5 mm before the ODD reduction was
calculated. ODD: optic disc dose, COMS: Collaborative Ocular Melanoma Study, DT: tumor margin-to-optic
disc distance, BD: basal dimension.
ODD reduction by 125I versus 103Pd notched COMS plaques with two seeds removed as a function of DT for
various BDs is plotted in Figure 7(a)-7(e). Trends of ODD reduction comparison between 125I and 103Pd
notched plaques with two seeds removed are similar to those with one seed removed but an ODD reduction
for 125I and 103Pd notched plaques is larger and ODD reduction differences between 125I and 103Pd notched
plaques are also larger for two seeds removal.
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FIGURE 7: (a)-(e) An ODD reduction comparison between 125I and
103Pd notched COMS plaques with two seeds removed as a function of
DT for various BDs.
A prescribed dose of 85 Gy was normalized to a central-axis depth of 5 mm before the ODD reduction was
calculated. ODD: optic disc dose, COMS: Collaborative Ocular Melanoma Study, DT: tumor margin-to-optic
disc distance, BD: basal dimension.
DCF comparison between 125I and 103Pd COMS plaques
Table 1 presents a comparison of DCFs for prescription depths from 2 mm to 10 mm between 125I and 103Pd
standard COMS plaques. DCF increases with increasing depth in each plaque for both seed types. However,
the increase is more drastic with 103Pd plaques. As a result, at a depth of <5 mm, DCFs for 103Pd plaques are
smaller than those for 125I plaques and absolute differences between the two seed types range from 0.01 to
0.03. On the other hand, at a depth of >5 mm, DCFs for 103Pd plaques are larger than those for 125I plaques
and absolute differences are much larger, increasing with increasing depth. For example, the largest absolute
difference for the 10 mm plaque is 0.45 (3.29 for 103Pd plaques versus 2.84 for 125I plaques) at a prescription
depth of 10 mm.
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Prescription depth (mm)
Plaque size in diameter (mm)
10 12 14 16 18 20 22
125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd
2 0.41 0.39 0.45 0.43 0.48 0.46 0.52 0.50 0.55 0.53 0.58 0.55 0.59 0.56
3 0.57 0.55 0.60 0.58 0.63 0.60 0.66 0.63 0.68 0.66 0.70 0.67 0.71 0.68
4 0.77 0.75 0.78 0.77 0.80 0.78 0.81 0.80 0.83 0.81 0.84 0.82 0.85 0.83
5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
6 1.27 1.31 1.25 1.29 1.23 1.27 1.22 1.25 1.20 1.23 1.18 1.21 1.18 1.20
7 1.59 1.68 1.54 1.63 1.50 1.59 1.47 1.55 1.43 1.50 1.40 1.46 1.38 1.44
8 1.95 2.13 1.88 2.05 1.82 1.97 1.76 1.91 1.69 1.82 1.64 1.76 1.61 1.72
9 2.37 2.66 2.27 2.54 2.18 2.43 2.10 2.33 2.00 2.21 1.92 2.12 1.87 2.06
10 2.84 3.29 2.71 3.13 2.59 2.98 2.48 2.84 2.34 2.67 2.24 2.54 2.17 2.45
TABLE 1: A comparison of DCFs (ratios of TRAK per seed) between 125I (model: IAI-125A) and
103Pd (model: IAPd-103A) standard COMS plaques.
The data were normalized to those for a prescription depth of 5 mm. DCF: dose conversion factor, TRAK: total reference air kerma, COMS:
Collaborative Ocular Melanoma Study.
Table 2 presents a comparison of DCFs for prescription depths from 2 mm to 10 mm between 125I and 103Pd
notched COMS plaques with one seed removed. Trends of DCFs for notched plaques are the same as those
for standard plaques: DCF increases with increasing depth in each plaque for both seed types. DCFs for
103Pd notched plaques are smaller than those for 125I plaques at a depth of <5 mm, whereas the opposite is
observed at a depth of >5 mm.
Prescription depth (mm)
Plaque size in diameter (mm)
12 14 16 18 20 22
125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd
2 0.45 0.42 0.48 0.45 0.52 0.49 0.55 0.52 0.57 0.55 0.58 0.55
3 0.60 0.57 0.62 0.60 0.65 0.63 0.68 0.65 0.70 0.67 0.70 0.68
4 0.78 0.76 0.80 0.78 0.81 0.79 0.83 0.81 0.84 0.82 0.84 0.83
5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
6 1.26 1.29 1.24 1.27 1.22 1.25 1.20 1.23 1.19 1.21 1.18 1.21
7 1.55 1.64 1.51 1.60 1.48 1.56 1.43 1.51 1.40 1.47 1.38 1.45
8 1.89 2.06 1.83 1.99 1.77 1.92 1.70 1.83 1.65 1.77 1.62 1.74
9 2.28 2.56 2.20 2.45 2.11 2.35 2.01 2.22 1.94 2.13 1.89 2.08
10 2.73 3.15 2.61 3.00 2.50 2.86 2.36 2.69 2.26 2.56 2.19 2.48
TABLE 2: A comparison of DCFs (ratios of TRAK per seed) between 125I (model: IAI-125A) and
103Pd (model: IAPd-103A) notched COMS plaques with one seed removed.
The data were normalized to those for a prescription depth of 5 mm. DCF: dose conversion factor, TRAK: total reference air kerma, COMS:
Collaborative Ocular Melanoma Study.
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A comparison of DCFs for prescription depths from 2 mm to 10 mm between 125I and 103Pd notched COMS
plaques with two seeds removed is shown in Table 3. Trends of DCFs for one seed removal are the same as
those for two seeds removal.
Prescription depth (mm)
Plaque size in diameter (mm)
14 16 18 20 22
125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd 125I 103Pd
2 0.48 0.45 0.52 0.49 0.55 0.52 0.57 0.54 0.57 0.54
3 0.62 0.60 0.65 0.63 0.67 0.65 0.69 0.67 0.70 0.67
4 0.80 0.78 0.81 0.79 0.83 0.81 0.84 0.82 0.84 0.82
5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
6 1.24 1.27 1.22 1.25 1.20 1.23 1.19 1.22 1.18 1.21
7 1.51 1.60 1.47 1.55 1.43 1.51 1.40 1.47 1.39 1.45
8 1.83 1.98 1.77 1.91 1.70 1.84 1.65 1.78 1.62 1.74
9 2.19 2.45 2.11 2.34 2.01 2.23 1.94 2.14 1.89 2.08
10 2.60 3.00 2.49 2.85 2.36 2.69 2.26 2.56 2.20 2.48
TABLE 3: A comparison of DCFs (ratios of TRAK per seed) between 125I (model: IAI-125A) and
103Pd (model: IAPd-103A) notched COMS plaques with two seeds removed.
The data were normalized to those for a prescription depth of 5 mm. DCF: dose conversion factor, TRAK: total reference air kerma, COMS:
Collaborative Ocular Melanoma Study.
Estimation of ODD: clinical application of this study
For a clinical example (BD = 6 mm, DT = 2 mm, and apical height = 4 mm), a practical application of the
results (figures and tables) from this study is shown in Table 4. A prescribed dose is 85 Gy and a 16 mm
COMS plaque is selected. Depending on the seed type (125I versus 103Pd), COMS plaque type (standard
versus notched), and prescription depth (COMS protocols versus ABS guidelines), 12 scenarios are possible,
and ODD can be estimated for each scenario (Table 4). From the 12 scenarios, the following trends are
observed. First, ODD for standard plaques is higher than that for notched plaques (scenarios #1 versus #2
and #3; scenarios #4 versus #5 and #6; scenarios #7 versus #8 and #9; scenarios #10 versus #11 and #12) for
the same seed type and for the same prescription depth. Second, ODD for a prescription depth of 5 mm
(COMS protocols) is higher than for a prescription depth of 4 mm (i.e., tumor apex; ABS guidelines,
scenarios #1-#6 versus #7-#12). Third, when 85Gy was prescribed at 5 mm, ODD (195.48 Gy) for the 103Pd
standard plaque is higher than that (190.43 Gy) for the 125I standard plaque. On the other hand, ODD (131.89
Gy) for the 103Pd notched plaque with one seed removed is similar to that (131.52 Gy) for the 125I notched
plaque with one seed removed and ODD (93.27 Gy) for the 103Pd notched plaque with two seeds removed is
lower than that (96.71 Gy) for the 125I notched plaque with two seeds removed. Fourth, when 85Gy was
prescribed at the tumor apex (i.e., 4 mm), ODD (156.38 Gy) for the 103Pd standard plaque is higher than that
(154.25 Gy) for the 125I standard plaque. The opposite trend is observed for notched plaques (106.53 Gy for
125I notched plaque with one seed removed versus 104.19 Gy for 103Pd notched plaque with one seed
removed; 78.34 Gy for 125I notched plaque with two seeds removed versus 73.68 Gy for 103Pd notched plaque
with two seeds removed). Therefore, among the 12 scenarios, the 103Pd standard plaque prescribed at 5 mm
and the 103Pd notched plaque with two seeds removed prescribed at 4 mm give the highest ODD (195.48 Gy
for scenario #4) and the lowest ODD (73.68 Gy for scenario #12), respectively, and the dose difference
between these two scenarios is 121.80 Gy (143.29% of the prescribed dose).
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TABLE 4: Twelve possible scenarios for a clinical example (BD = 6 mm, DT = 2 mm, and apical
height = 4 mm in 16 mm COMS plaques) and corresponding estimated ODDs
BD: basal dimension, DT: tumor margin-to-optic disc distance, COMS: Collaborative Ocular Melanoma Study, ODD: optic disc dose.
Discussion
This study has demonstrated that ODD has a dependence on DT, BD, plaque size, and prescription depth,
and the trends of ODD for 125I standard and notched COMS plaques are similar to those for 103Pd standard
and notched COMS plaques, respectively (Figures 3-5). ODD usually decreases with increasing DT mainly
due to the inverse square law. For the same DT in each plaque, ODD decreases with increasing BD because
the distance from plaque to optic disc increases with increasing BD. Since the diameter of the plaque, the
number of seeds, and seed configurations depend on the plaque [2], ODD varies with plaque size. ODD
increases with increasing prescription depth because a deeper depth requires greater TRAK per seed (Tables
1-3).
Despite the aforementioned similarities, there are differences in ODD between 125I and 103Pd COMS plaques
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(Figures 3-5). The differences result from the difference in average photon energy between the two seed
types (28 keV for 125I seeds versus 21 keV for 103Pd seeds) which leads to a more drastic decrease of relative
dose with distance for 103Pd seeds than for 125I seeds [9]. Therefore, ODD for 103Pd plaques is higher at
relatively short DT and becomes lower at longer DT than ODD for 125I plaques. As a result, there exists the
transition point (i.e., dt) at which ODD for 
103Pd plaques is the same as that for 125I plaques. For small BDs
in each plaque, dt becomes closer to the optic disc with increasing BD because the region of drastic dose fall-
off within the tumor increases as BD increases.
ODD reduction by notched COMS plaques has unique trends and there are similarities and differences in
ODD reduction between 125I and 103Pd notched COMS plaques (Figures 6 and 7). Reasons for the unique
trends of ODD reduction are detailed in Lee et al. [13]. Similarities in ODD reduction between the two seed
types can be explained by the reasons. Differences in ODD reduction between the two seed types result from
the energy difference. Because of the lower energy and more rapid dose fall-off with increasing DT, ODD
reduction by 103Pd notched plaques is larger than that by 125I notched plaques, and therefore, 
 for 103Pd notched plaques is larger (Figures 6 and 7). However, for each plaque,
there is no difference in DTmaxD (DT at which  occurs) between the two seed
types because the number of seeds and seed configurations in each plaque is the same for both seed types.
There are similarities and differences in DCFs between 125I and 103Pd COMS plaques (Tables 1-3). DCF for
both seed types increases with increasing prescription depth because a deeper depth requires greater TRAK
per seed (Tables 1-3). Since dose fall-off along the central axis of the plaque is more rapid with 103Pd
plaques, at prescription depths shallower than 5 mm, the central-axis dose for 103Pd plaques is higher than
that for 125I plaques, and thus, smaller DCFs are required with 103Pd plaques. At prescription depths deeper
than 5 mm, the central-axis dose for 103Pd plaques becomes lower, and thus, larger DCFs are required with
103Pd plaques. As a result, DCF for 103Pd plaques increases more rapidly with increasing prescription depth
than that for 125I plaques. Both standard and notched COMS plaques have these trends.
Data for the other prescription depths can be obtained from the data provided in this study. In this study,
ODD for both seed types and ODD reduction by notched plaques for both seed types were presented only
for a prescription depth of 5 mm. Yet, corresponding data for the other prescription depths would be
different. From ODD (Figures 3-5) for a depth of 5 mm and DCFs (Tables 1-3) for depths of 2-4 mm and 6-10
mm, one can calculate ODD for any prescription depth and compare ODD between 125I and 103Pd COMS
plaques.
The clinical example comparing ODDs among 12 different scenarios would help the clinician choose the best
option to minimize ODD. As shown in Table 4, for tumors with apical height <5 mm, seed type (125I or
103Pd), COMS plaque type (standard or notched), and prescription depth (5 mm or tumor apex) affect ODD.
ODD for 103Pd seeds is not always lower than that for 125I seeds, contradicting the study by Finger et al. [9].
ODD for 125I seeds can be lower when the tumor is closer to the optic disc than d t (scenarios #1 versus #4).
Notched plaques are usually beneficial in reducing ODD. Prescribing to a shallower depth is also beneficial
in reducing ODD. For tumors with apical height ≥5 mm, however, a prescription depth is always the tumor
apex and thus, a prescription depth would not be a parameter to reduce ODD.
One limitation of this study is that heterogeneity corrections were not taken into account. It has been
reported that dose attenuated in the silastic insert and gold plaque is significant (≥10%) [15]. Hence, the
ODD presented in this study would be overestimating. AAPM TG 129 and AAPM TG 221 recommend the TG-
43 calculations along with heterogeneity corrections [2,16]. A future study using a more accurate dose
calculation tool such as Plaque Simulator (Eye Physics LLC, Los Alamitos, CA) or another Monte Carlo
simulation would warrant accurate ODD.
Conclusions
This study has demonstrated that ODD has dependence on DT, BD, plaque size, plaque type, prescription
depth, and seed type. Trends of ODD as a function of DT for various BDs are similar between 125I and 103Pd
seeds for both standard and notched COMS plaques. However, due to the energy difference between the two
seed types resulting in different relative dose variations with distance, there exists a transition distance (dt)
for each BD in each plaque at which ODD for 125I plaques equals that for 103Pd plaques. For small BDs, at DT
<dt, ODD for 
103Pd plaques is higher than that for 125I plaques while at DT >dt, the opposite is observed. For
the largest 1-3 BDs, contrarily, dt exists within the tumor and thus, ODD for 
125I plaques is always higher
than that for 103Pd plaques. Trends of ODD reduction by notched plaques as a function of DT for various BDs
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than that by 125I notched plaques. ODD and DCF increase with increasing prescription depth for both seed
types but DCF for 103Pd plaques increases more drastically than for 125I plaques.
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